BioSpace News Archive

Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), today announced that it will report financial results for the third quarter ended September 30, 2022 on Monday, November 14, 2022, before the open of U.S. markets.

ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation, announced today that its proprietary ECT-001 Cell Therapy has been administered to 100 patients.

Avenue Therapeutics, Inc. today announced the closing of the acquisition of Baergic Bio, Inc. (“Baergic Bio”) pursuant to the previously disclosed Share Contribution Agreement with its parent company, Fortress Biotech, Inc.

SAB Biotherapeutics today announced the company will be attending and presenting at this year’s U.S. Pharma Partnering Summit, being held on Nov. 17-18 in Boston, MA.

Processa Pharmaceuticals, Inc. announces positive gastric emptying results from its PCS12852 Phase 2A trial in patients with moderate to severe gastroparesis.

Anixa Biosciences, Inc. today announced a presentation outlining the design of its ongoing breast cancer vaccine trial on December 7, 2022 , at the 2022 San Antonio Breast Cancer Symposium.

Evolution Optiks Limited, a global leader in light field technology applications, announced today the completion of enrollment of the pivotal U.S. Food and Drug Administration (FDA) clinical study to evaluate the safety and efficacy of its subjective light field LFR-260 tele-phoropter (investigational device).

Notch Therapeutics, Inc. is pleased to welcome new members to its Scientific Advisory Board (SAB).

Blue Earth Therapeutics Awarded UK MHRA Innovation Passport for Investigational 177 Lu-rhPSMA-10.1 for Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC).

Immunomic Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to the ITI-3000 program for the treatment of patients with Merkel cell carcinoma.